New York, May 23, 2026, 15:03 EDT
- Microbot Medical shares ended Friday at $1.71, off 3.93%. The stock shed about 7.6% for the week.
- Stocks climbed in the U.S. on Friday, the Nasdaq Composite gaining 0.19%. Markets will be shut Monday for Memorial Day.
- The focus is now on early LIBERTY revenue and new accounts, set against lagging sales, losses and a recent short-seller push.
Microbot Medical Inc. stock slipped Friday, closing at $1.71, down 3.93%, with volume at about 1.29 million shares, according to the company’s LSEG-sourced data. The move put pressure on shares heading into the holiday-shortened week, as MBOT lagged while U.S. indexes climbed.
The shift is important now as the company ramps from a limited launch to full commercial rollout of its LIBERTY endovascular robotic system. Endovascular procedures use catheters to work within blood vessels.
Microbot is moving past its development stage, but the company hasn’t shown big adoption yet. This month, Microbot said its second-quarter revenue has already passed what it made in the first quarter, and the company said accounts more than doubled from the end of its limited launch.
The shares didn’t match the company’s message. The stock finished the week lower from $1.85 last Friday, with market cap most recently around $115 million.
Microbot Medical Inc’s Q1 filing put revenue at $105,000 with a $103,000 cost of revenue, and net loss widened to $3.7 million from $2.6 million a year ago. At March 31, it listed $3.7 million in cash and cash equivalents, plus $68.8 million of marketable securities.
Microbot Medical Inc CEO Harel Gadot said second-quarter momentum was “encouraging,” pointing to “recurring orders” as the company grew into more states. He said Microbot expects to expand into “population-rich regions” across the U.S. later this year. Microbot Medical Inc
LIBERTY drew a lot of attention last week after a credibility fight hit the market. According to Investing.com, MBOT shares slid when White Diamond Research, which holds a short position, raised doubts about whether the system can work commercially. A short position bets the stock will drop.
Microbot said it has set up an analyst and investor call for May 18 to respond to what it calls misrepresentations in a third-party article not linked to the company. The firm said Dr. Charles Briggs, a vascular surgeon at Tampa General Hospital, and Dr. Zachary Bercu from Emory Healthcare will join its executives on the call to talk about use of LIBERTY.
The competitive field is small but active. Siemens Healthineers calls its CorPath GRX a vascular robotic system for coronary and peripheral work. Stereotaxis offers robotic magnetic navigation systems. Intuitive Surgical is still the main name in surgical robotics with da Vinci, but it doesn’t compete directly in endovascular systems.
Microbot’s pitch is its disposable, remote-controlled system. The company’s filing says LIBERTY is built for moving guidewires and catheters through blood vessels, cuts down on radiation and strain for users, and skips some of the big equipment that comes with older robotic setups.
But the risk is clear. Microbot said in its latest quarterly filing that it hasn’t seen much revenue and still expects to post losses while manufacturing and sales pick up. The company set up an at-the-market facility to sell up to about $39.2 million in stock over time. If hospital orders stay slow, or if there’s more dilution or heavy short selling, shares could struggle to get off Friday’s low.
Nasdaq has Monday, May 25, as a Memorial Day market holiday, so the next session is set for Tuesday, May 26. MBOT traders are watching the $1.70 intraday low from Friday and looking to see if the company gives fresh proof that initial account wins are becoming repeat business.
